Full-Time

Discovery Research Procurement Lead

R&D Procurement

Posted on 11/23/2025

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$208.2k - $327.1k/yr

Cambridge, MA, USA

Hybrid

Onsite requirement: at least 8 days per month; must live within a commutable distance to Cambridge, MA.

Category
Operations & Logistics (1)
Required Skills
Risk Management
Requirements
  • BA or BS required, MBA or Master’s Degree with Supply Chain/Procurement emphasis preferred. Degree in Business Administration, Chemistry, Biology, or a related field preferred.
  • 15 plus years in-depth strategic and operational procurement experience with extensive knowledge of category management and advanced strategic sourcing methodologies
  • Minimum of 15 years working in biotech/pharma industry, or other highly regulated industries, with progressive leadership of procurement
  • Possess in-depth knowledge of Category Management and Supplier Relationship Management
  • Experience in managing large groups with senior procurement professionals
  • Experience working in a complex global environment
  • Exceptionally skilled at stakeholder management including senior/executive levels
  • Strong and proven business partnering, negotiation, leadership, communication and change management skills
  • Direct experience in managing category management and development of category strategies
  • Direct experience of executing and leading operational buying activities
  • Proven Financial and Business Acumen
  • Change management and process improvement skills with direct experience in delivering business process change
Responsibilities
  • Establish and maintain excellent collaborative relationships with key business stakeholders including Research, Finance and Global Quality globally to ensure that regional and global business goals and objectives are met
  • Serve as a highly influential leader within the business impacting decisions within Takeda R&D and beyond to deliver high quality strategy and outcomes
  • Socialize procurement and category management best practices within the business (i.e. increased utilization of preferred suppliers, SoW optimization and the use of BuyEasy@Takeda etc.)
  • Champion procurement policy and wider procurement initiatives, articulating their importance, value and reasoning as required (for example, Ways of Working, Sustainability, Supplier Diversity, etc.)
  • Collaborate and provide strategic guidance to the business regarding annual planning, budgeting, and forecasting cycle
  • Align inputs from business planning and budgeting with the procurement annual plan
  • Respectfully challenge key category stakeholders based on Patient-Trust-Reputation-Business decisions as part of the business decision making process
  • Develop strong working relationships with the wider Takeda business (including supporting functions such as Legal Operations, Takeda Business Solutions etc.) to ensure alignment on key topics relevant to the Procurement function
  • Lead the development and implementation of the Category strategy at both the category and sub-category levels with support of the Category Managers in alignment with organizational objectives, market dynamics and internal stakeholder needs
  • Manage strategic initiatives across the Category (i.e. Category Councils, engagement guidelines, cash flow initiatives, risk management, etc.) ensuring alignment between category activities and both regional/global requirements
  • Successfully create and execute Procurement annual plan (global/regional as required) using both external and internal market intelligence
  • Collaborate with global and regional Procurement teams, Takeda Business Services, Legal and other functions to help implement the most effective category strategies including buying channels and negotiation strategies
  • Champion Takeda values and initiatives including supplier diversity and sustainability across procurement, supporting functions and the wider Takeda business
  • Support Category Managers with the effective communication of category strategies, performance metrics (KPIs) and initiatives to internal stakeholders and senior management
  • Ensure oversight of the internal category management processes to enable timely escalation and resolution of category specific issues
  • Sponsor the development of a frictionless, rapid, and effective day-to-day buying experience within the category taking into account business needs and feedback
  • Ensure the translation of the relevant category strategy(s) into day-to-day buying activity through the development and maintenance of best practice buying channels, procurement content (pricing, terms, service catalogues, buying guides etc)
  • Accountable for the realization of savings on each day-to-day buy through the effective application of rates, appropriate demand management techniques, and where applicable negotiation with suppliers.
  • Oversee discussions between category leadership, Global Procurement Centre of Excellence, Takeda Business Services (TBS), Legal Operations, Finance, IT and other relevant stakeholders to drive process and systems improvements that create a better day to day buying experience for stakeholders and improves value realization by Takeda.
  • Provide regular feedback to those conducting operational buying to drive continuous improvement.
  • Clearly demonstrate, actively coach and encourage the team to adopt the Takeda Leadership Behaviors (Think Strategically, Inspire others, Deliver Priorities, Elevate Capabilities)
  • Establish and communicate clear roles and responsibilities to the category team and key business stakeholders and functions
  • Drive performance excellence by setting clear expectations and providing constructive feedback
  • Lead, coach and mentor to enhance the team’s skills and capabilities both in the Procurement team and other functions
  • Conduct individual performance management processes for all direct reports and additional key partners (as required, 360 feedback reviews) while also supporting and championing development plans for direct reports,
  • Coach Category Managers to deliver contract negotiations on behalf of Takeda to secure favorable terms, pricing and statements of work, while ensuring compliance with legal and regulatory requirements.
  • Engage in regular quality conversations with all direct reports and additional key partners (as required)
  • Support and champion the creation and execution of development plans for all direct reports
  • Develop a succession plan for the team that supports career development and ensure a pipeline of talent is available
  • Foster a climate that inspires, enables, encourages open dialogue, feedback and diverse opinions
  • Promote collaboration, trust and respect among team members and the wider Takeda business
  • Guide and support the team through periods of change
  • Ensure compliance with Takeda training requirements (all team members)
Desired Qualifications
  • Experience with ESG initiatives such as supplier diversity and Scope 3 emissions
  • Experience leading development and execution of global category strategies
  • Experience leading and managing large global procurement teams
  • Proficiency with Microsoft Office Suite and other standard tools

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Zasocitinib NDA submission planned FY2026 challenges Bristol Myers Squibb's Sotyktu.
  • Rusfertide PDUFA target Q3 2026 under FDA Priority Review boosts polycythemia vera pipeline.
  • Stock undervalued at ¥5,173 versus ¥6,036 fair value with post-FY2025 revenue recovery.

What critics are saying

  • VYVANSE generic erosion crushes revenue beyond FY2025 stabilization.
  • 634 US layoffs from July 2026 trigger talent exodus to Vertex.
  • JPY 150B FY2026 restructuring costs overrun delays oveporexton launch.

What makes Takeda unique

  • Takeda advances zasocitinib oral TYK2 inhibitor with positive Phase 3 LATITUDE data.
  • Takeda secures exclusive global rights to rusfertide after Protagonist opt-out.
  • Takeda restructures for $1.25B savings by FY2028 to fund multiple launches.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Takeda who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Apr 6th, 2026
Takeda breaks up with Denali, dumps dementia drug.

Takeda breaks up with Denali, dumps dementia drug. April 6, 2026 | Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer's disease, was previously discontinued after an FDA hold and disappointing early data. More than eight years after linking up, Takeda and Denali Therapeutics are going their separate ways, with the Japanese pharma handing all rights to a dementia program back to Denali. Takeda's decision to terminate its partnership with Denali "was driven by strategic considerations," the California biotech said in an SEC document dated April 3, and "is not related to efficacy or safety data." The Japanese pharma informed Denali of its decision that same day, according to the securities filing. The companies inked their partnership in January 2018, with Takeda fronting $150 million and promising unspecified milestone payments. Takeda and Denali had also previously been working on the TREM2 agonist DNL919 for Alzheimer's disease - but this molecule's development path has been bumpy. In January 2022, the FDA slapped a clinical hold on the asset, though the partners at the time did not disclose why. The hold was eventually lifted, but Takeda and Denali in August 2023 nevertheless discontinued DNL919's development, pointing to Phase 1 findings suggesting the drug had only a "narrow therapeutic window." In 2021, Takeda also exercised its option to co-develop and co-commercialize DNL593, a protein replacement therapy that can cross the blood-brain barrier, for frontotemporal dementia. That asset has since been returned to Denali, the biotech said on April 3. "We are looking forward to advancing DNL593 independently," CEO Ryan Watts said in a press statement that day, adding that the company "remain[s] confident" in the scientific rationale behind DNL593. DNL593 works by replacing the progranulin protein, which in frontotemporal dementia is deficient, leading to lysosomal defects that, in turn, result in the accumulation of toxins across different tissues. The asset is currently in a Phase 1/2 study, enrollment for which has completed with 40 recruited participants, according to Denali's April 3 release. There have been no reported safety signals to date, the biotech noted. Phase 1/2 data for DNL593 are expected before the end of this year, Watts said. Takeda's pullback comes just days after Denali delivered a much-needed win for the rare disease space with the FDA approval of its Hunter syndrome therapy Avlayah. Like DNL593, Avlayah works by replacing a deficient player, this time targeting the IDS enzyme, which under healthy conditions clears toxic byproducts from several organs, including the brain. Avlayah is the first Hunter syndrome therapy in nearly 20 years and is the first FDA-approved treatment to exploit the transferrin pathway to cross the blood-brain barrier. Avlayah is the first Hunter syndrome therapy approved to address the condition's neurologic complications, according to Tracy Beth Høeg, acting director of the Center for Drug Evaluation and Research. March 26, 2026

The Boston Globe
Mar 31st, 2026
Pharma giant Takeda to lay off nearly 250 local workers in latest job cutting.

Pharma giant Takeda to lay off nearly 250 local workers in latest job cutting. By Marin Wolf Globe Staff, Updated March 30, 2026, 10:00 a.m. Takeda Pharmaceuticals will lay off nearly 250 workers in Cambridge, the state's largest biopharma employer announced through a state filing. The layoffs will begin in July, although some will take place later in the year or in 2027. All affected Massachusetts employees work at the company's 500 Kendall St. location, according to the filing posted Friday. The workforce reduction is part of a cost-saving plan approved by Takeda's board of directors on March 25 that is expected to result in annual savings of about $1.25 billion by 2028, according to a company statement. Another 387 workers in other states may also be laid off as part of the plan.

Yahoo Finance
Mar 30th, 2026
Takeda Pharmaceuticals to cut 247 jobs in Cambridge as part of $1.2B cost-cutting plan

Takeda Pharmaceuticals, Massachusetts' largest biopharmaceutical employer, will lay off 247 employees at its Cambridge headquarters as part of a broader corporate restructuring. The redundancies begin on 1 July and could extend into 2027. The Japanese company announced cost-cutting measures expected to save approximately $1.2 billion by 2028. An additional 387 employees will be laid off in other US states. Affected workers are receiving transition assistance, including help identifying internal opportunities. Takeda currently has around 700 open positions, including 300 in Massachusetts, with internal candidates given priority. The company employs more than 5,700 people in Massachusetts and occupies approximately 2.8 million square feet of real estate. This follows 137 layoffs announced in October and over 800 Massachusetts redundancies in 2024.

BioSpace
Mar 30th, 2026
Takeda restructuring could push more than 600 US staffers out of jobs.

Takeda restructuring could push more than 600 US staffers out of jobs. March 30, 2026 | Takeda's layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data. The workforce impact of Takeda's recently announced reorganization has become clearer. The Japan-based pharma estimates the restructuring will affect around 634 U.S. employees, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Takeda began notifying employees on March 25, the same day it announced a business transformation, which includes streamlining corporate functions. However, the company noted in the WARN notice that the total number affected could change as staff pursue and accept redeployment opportunities across its global network. Takeda's cuts include 247 employees in Cambridge, Massachusetts, effective July 1, 2026, through Dec. 31, 2027. To understand where other layoffs will take place, BioSpace has requested a copy of a document mentioned in the WARN notice that lists the number of individuals affected by state. In last week's announcement, Takeda noted that the restructuring, which includes "strategically prioritizing resources," is expected to save more than 200 billion yen - about $1.25 billion - by fiscal year 2028. The company explained that the savings will offset investments needed to prepare for multiple launches, including oveporexton, usfertide and zasocitinib; progress the late-stage pipeline; and support strategic technology investments. Takeda announced today promising data for zasocitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate to severe plaque psoriasis. In the Phase 3 Latitude PsO 3001 and 3002 studies, more than half of patients treated with the drug candidate achieved clear or almost clear skin at week 16, a key measure of treatment success, according to the pharma. Zasocitinib also demonstrated statistically significant improvements in complete skin clearance. Takeda expects to submit a new drug application for zasocitinib in fiscal year 2026. The pharma acquired zasocitinib from Nimbus Therapeutics for $4 billion at the end of 2022 to challenge Bristol Myers Squibb's kinase inhibitor Sotyktu. Takeda in December 2025 reported positive results from the Phase 3 LATITUDE studies, noting that when compared with placebo and Amgen's Otezla, about 30% of treated patients achieved completely clear skin, or a score of 100 on the Psoriasis Area and Severity Index (PASI). The company's latest layoffs join a series of cuts from the past two years. Takeda let go of nearly 1,500 employees in the U.S. and Austria in 2024 and early 2025 and 137 in October 2025. In January, news broke that 243 people would be laid off across its U.S. operations.

Healthcare Asia Magazine
Mar 30th, 2026
Takeda Healthcare Philippines, Inc. wins at Healthcare Asia Pharma Awards 2026.

Takeda Healthcare Philippines, Inc. wins at Healthcare Asia Pharma Awards 2026. The access programme and advocacy initiative closed affordability gaps for Filipino patients. Takeda Healthcare Philippines, Inc. won Most Differentiated Service of the Year - Philippines and Patient Advocacy Program of the Year - Philippines in the Healthcare Asia Pharma Awards 2026 for its access model that supports patients from disease awareness to therapy completion. In a healthcare system where many patients face delayed diagnosis, long referral pathways, and high out-of-pocket costs, the company built a differentiated and sustainable service anchored on its Patient Assistance Program (PAP). The programme follows a clear principle: therapy completion should not depend on a patient's ability to pay. PAP uses an affordability-based assessment to evaluate each eligible patient's circumstances and set a contribution aligned to what the patient can reasonably afford for the full course of treatment. This structured, patient-level approach supports equity whilst maintaining business viability. It is not a standard discount model but a tailored access scheme designed for Filipino patients and adaptable to changing circumstances. The operating model involves independent third parties assessing financial support needs and informing programme design. Patients share in the cost of treatment, whilst Takeda Healthcare Philippines, Inc. collaborates with local authorities and partners to help cover the remaining cost. The company embeds access within hospital pathways through collaborations with organisations such as the Tzu Chi Foundation, private institutions, and major hospitals, helping reduce out-of-pocket expenses and improve coordination across the patient journey. Join Healthcare Asia Magazine community To date, more than 1,300 Filipino patients have received support through Takeda's access programme, including patients living with Hodgkin lymphoma, inflammatory bowel disease, and other rare conditions. By enabling therapy completion, the programme helps patients return to work or school and resume caregiving roles, reducing the broader social and economic burden of untreated disease. Beyond affordability, the company addresses inequity in geographically isolated and disadvantaged areas by working with partners to strengthen patient navigation and connections to appropriate providers and specialists. Through Access to Medicines Summits and partnership frameworks, it also supports patients in accessing available private and government funding. A key milestone in its advocacy efforts is the inclusion of life-saving treatment for rare diseases such as haemophilia in the Philippine National Formulary, enabling free access to essential medicines in government hospitals following partnerships and a positive health technology assessment. The Healthcare Asia Pharma Awards shines a spotlight on the outstanding companies redefining pharmaceutical excellence in Asia. It lauds those who redefine the pharmaceutical landscape through innovative, unique initiatives that have significantly enhanced their businesses. The Healthcare Asia Pharma Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be recognised for your organisation's innovative and unique initiatives that enhanced your business and remarkable contributions to the pharmaceutical industry, please contact Julie Anne Nuñez-Difuntorum at [email protected].

INACTIVE